NASDAQ:CNSY Plus Therapeutics Q2 2026 Earnings Report $2.02 +0.03 (+1.51%) Closing price 09/28/2026 04:00 PM EasternExtended Trading$2.00 -0.02 (-1.24%) As of 07:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Plus Therapeutics EPS ResultsActual EPS-$1.31Consensus EPS -$0.96Beat/MissMissed by -$0.35One Year Ago EPSN/APlus Therapeutics Revenue ResultsActual Revenue$0.41 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APlus Therapeutics Announcement DetailsQuarterQ2 2026Date8/14/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Plus Therapeutics Earnings HeadlinesCerenome to Hold CNSide® Business Update Call on September 30, 2026September 25, 2026 | globenewswire.comCerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered LivesSeptember 22, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 29 at 1:00 AM | Chaikin Analytics (Ad)CNSY Q3 EPS Forecast Decreased by Ascendiant Capital MarketsSeptember 19, 2026 | americanbankingnews.comCerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics DivisionSeptember 16, 2026 | globenewswire.comCERENOME INCSeptember 11, 2026 | finanznachrichten.deSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:CNSY) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company’s lead investigational product is Rhenium-186 NanoLiposome, or 186RNL, a nanoliposome-based formulation designed to deliver the beta-emitting radioisotope rhenium-186 directly to tumor sites. Plus Therapeutics is evaluating 186RNL in clinical programs for recurrent glioblastoma and leptomeningeal metastases, cancers that spread to the membranes surrounding the brain and spinal cord. The company’s approach is intended to provide localized radiation while limiting exposure to surrounding healthy tissue. These programs remain investigational and have not established the product as an approved commercial treatment. Based in Austin, Texas, Plus Therapeutics serves the oncology market through research and clinical development activities conducted primarily in the United States. Marc Hedrick, M.D., has served as the company’s president and chief executive officer. The company has also pursued collaborations and government-supported development efforts related to its targeted radiotherapeutic platform.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
